ClinicalTrials.gg
CompletedNCT01462344VESTRIUpdated Aug 6, 2018Results posted

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

A Phase 4 interventional study of ADVAIR 100/50mcg and ADVAIR 250/50mcg in Asthma, sponsored by GlaxoSmithKline. Completed at 532 sites in 32 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2018-08-06.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6,250
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
2nd of 146
6,250 · median 100
Started
2011
with 7 others
Phase 4
52 of 147
1 open now
Registered
81st of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 2nd largest by enrollment of the 146 interventional ones that give a count, is one of 8 that started in 2011, is one of 52 in phase 4, and was the 81st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.

Read the detailed description

Progress of Enrollment, Updated Annually: This study has been completed and the final clinical study report was submitted to the FDA in May of 2016. This is the final update, as this study is complete.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • pediatric
  • ADVAIR
  • FLOVENT
  • asthma
04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Consent to participate in the study
  2. Age 4-11 years old
  3. Male or eligible female - Female subjects should not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study participation
  4. Asthma diagnosis for at least 6 months
  5. Ability to answer questions regarding asthma control and use a metered dose inhaler and DISKUS
  6. A history of clinical varicella infection or recipient of a varicella vaccine in countries where the product label includes a warning regarding more serious chickenpox infections in patients using .
  7. History of at least once occurrence of asthma exacerbation within the prior 12 months
  8. Currently being treated for asthma and no change in asthma therapy for the last 4 weeks (Eligible subjects include: subjects with use of short-acting beta-agonist, leukotriene receptor antagonist, theophylline, or cromolyn whose asthma is not well-controlled; subjects on low-dose ICS monotherapy whose asthma is not well-controlled; subjects on low-dose ICS and one or more adjunctive therapy whose asthma is either controlled or not well-controlled asthma; subjects on medium-dose ICS monotherapy whose asthma is either controlled or not well-controlled; and subjects on medium-dose ICS and one or more adjunctive therapy whose asthma is well-controlled)

Exclusion criteria

Exclusion Criteria:

  1. History of life-threatening asthma
  2. Unstable asthma
  3. Current use of high-dose ICS or ICS/LABA therapy to treat asthma symptoms
  4. Concurrent respiratory disease: Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other severe respiratory abnormalities other than asthma.
  5. Respiratory infection
  6. Subjects with only exercise-induced asthma
  7. An asthma exacerbation within the last 4 weeks or more than 4 separate exacerbations in the last 12 months
  8. Hospitalization for asthma within 4 weeks or more than 2 hospitalizations within the last 12 months
  9. Other current evidence of uncontrolled disease/conditions of any body or organ system
  10. Neurological or psychiatric disease or history of drug or alcohol abuse of a subject or his/her guardian which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirements
  11. Participation in an interventional study or used any drug for any disease state within the last 30 days
  12. Any adverse reaction including immediate or delayed to any beta-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic therapy, or vehicle contained within these medication
  13. Severe hypersensitivity to cow's milk proteins
  14. Administration of prescription or over the counter medications that would significantly affect the course of asthma, or interact with sympathomimetic amines such as: anti-IgE (omalizumab), anticonvulsants (barbiturates, hydantoins, carbamazepine); polycyclic antidepressants, beta-adrenergic blockers; phenothiazines, monoamine oxidase inhibitors, or diuretics
  15. Potent cytochrome P450 3A4 () inhibitors within the last 4 weeks (e.g., ritonavir, ketoconazole, itraconzole)
  16. Affiliation with investigator's site, including a immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
  17. A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6,250 participants (actual)

Study arms

  • Experimental
    ADVAIR 100/50mcg

    fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months

    Drug: ADVAIR 100/50mcg

  • Experimental
    ADVAIR 250/50mcg

    fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months

    Drug: ADVAIR 250/50mcg

  • Active comparator
    FLOVENT 100mcg

    fluticasone propionate (100) twice daily (AM and PM) for 6 months

    Drug: FLOVENT 100mcg

  • Active comparator
    FLOVENT 250mcg

    fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months

    Drug: FLOVENT 250mcg

Interventions

  • DrugADVAIR 100/50mcg

    fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months

    Also known as: FSC 100/50

  • DrugADVAIR 250/50mcg

    fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months

    Also known as: FSC 250/50

  • fluticasone propionate (100) twice daily (AM and PM) for 6 months

    Also known as: FP 100

  • fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months

    Also known as: FP 250

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)

    Composite endpoint was defined as clinically relevant endpoint that is constructed from combinations of other clinically relevant endpoints of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death). Hospitalization was defined as an inpatient stay or a \>=24-hour stay in an observation area in an emergency department or other equivalent facility. Time to first event in the composite endpoint of serious asthma-related outcomes over the 6-month study treatment period was analyzed using a Cox proportional hazards regression model. An estimate of absolute risk difference and its corresponding 95% confidence interval (CI) were also included. The Intent-to-Treat (ITT) Population included all participants randomized to study drug and who took study treatment.

    Time frame: From Day 1 up to 6 months

  2. Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period

    Number of participants with asthma exacerbation over the 6-month study treatment period are presented. Participants from mITT population with screening childhood asthma control test (C-ACT) scores of 20 or higher, one exacerbation in the previous year, and either low-dose inhaled corticosteroid (ICS) + one or more adjunctive therapy or medium-dose ICS monotherapy or medium-dose ICS and one or more adjunctive therapy as prior asthma therapy were included for this endpoint. Time to first exacerbation analyzed using a cox proportional hazards regression model. The number of asthma exacerbations were compared between treatments using a negative binomial regression model. The modified Intent-to-Treat (mITT) Population consisted of the ITT participants with a different data cut-off for supportive analyses of the primary composite safety endpoint.

    Time frame: From Day 1 up to 6 months

Secondary outcomes

  1. Number of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period.

    Number of participants experiencing asthma-related death over the 6-month study treatment period are presented.

    Time frame: From Day 1 up to 6 months

  2. Number of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period

    Intubation is defined as endotracheal intubation with ventilation (mechanical or by hand). The number of participants experiencing asthma-related endotracheal intubations over the 6-month study treatment period are presented.

    Time frame: From Day 1 up to 6 months

  3. Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period

    Hospitalization is defined as a \>=24-hour stay as an inpatient or in an observation ward. The number of participants experiencing asthma-related hospitalizations over the 6-month study treatment period are presented.

    Time frame: From Day 1 up to 6 months

  4. Number of Participants Withdrawn From Study Treatment Due to Asthma Exacerbation Over the 6-month Study Treatment Period

    An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days (up to 10 days) or a single depot corticosteroid injection. Number of participants experiencing at least one exacerbation from mITT population were included for this endpoint. The number of participants withdrawn from study treatment due to asthma exacerbation over the 6-month study treatment period are presented.

    Time frame: From Day 1 up to 6 months

  5. Percentage of Rescue-free Days Over the 6-month Study Treatment Period

    Rescue-free days were days without use of rescue albuterol/salbutamol (other than pre-exercise treatment) over the 6-month study treatment period. The mean percentages of rescue-free days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.

    Time frame: From Day 1 up to 6 months

  6. Percentage of Asthma Control Days Over the 6-month Study Treatment Period

    An asthma control day is one on which rescue albuterol/salbutamol use was recorded as 0, no night time awakenings were recorded, no asthma exacerbations were recorded, no work, school, or daycare days were missed by caregiver or participant due to asthma, coughing symptom score was \<=1 and wheezing symptom score was 0. The mean percentages of asthma control days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.

    Time frame: From Day 1 up to 6 months

07

Results

Posted Oct 5, 2016

Participant flow

A total of 6250 participants were enrolled and randomized to study treatments; total 6208 participants took at least one dose of study drug.

Participant flow — Overall Study
MilestoneFluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)
Started31073101
Completed27242751
Not completed383350
Withdrew: Withdrawal by subject245226
Withdrew: Adverse event2423
Withdrew: Asthma exacerbation3435
Withdrew: Lack of efficacy56
Withdrew: Protocol violation6853
Withdrew: Lost to follow-up77

Outcome measures

PrimaryNumber of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)

Composite endpoint was defined as clinically relevant endpoint that is constructed from combinations of other clinically relevant endpoints of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death). Hospitalization was defined as an inpatient stay or a \>=24-hour stay in an observation area in an emergency department or other equivalent facility. Time to first event in the composite endpoint of serious asthma-related outcomes over the 6-month study treatment period was analyzed using a Cox proportional hazards regression model. An estimate of absolute risk difference and its corresponding 95% confidence interval (CI) were also included. The Intent-to-Treat (ITT) Population included all participants randomized to study drug and who took study treatment.

Time frame:
From Day 1 up to 6 months
Reported as:
Number · Participants
Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)
ParticipantsFSC DPIFP DPI
Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)2721
Statistical analysis
  • FSC DPI vs FP DPI · Regression, Cox · p = 0.006 · Hazard ratio (hr): 1.285 · 95% CI 0.726 to 2.272Estimated for Hazard ratio
  • FSC DPI vs FP DPI · Risk difference (rd): 0.0019 · 95% CI -0.0024 to 0.0063Estimated for Absolute risk difference
PrimaryNumber of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period

Number of participants with asthma exacerbation over the 6-month study treatment period are presented. Participants from mITT population with screening childhood asthma control test (C-ACT) scores of 20 or higher, one exacerbation in the previous year, and either low-dose inhaled corticosteroid (ICS) + one or more adjunctive therapy or medium-dose ICS monotherapy or medium-dose ICS and one or more adjunctive therapy as prior asthma therapy were included for this endpoint. Time to first exacerbation analyzed using a cox proportional hazards regression model. The number of asthma exacerbations were compared between treatments using a negative binomial regression model. The modified Intent-to-Treat (mITT) Population consisted of the ITT participants with a different data cut-off for supportive analyses of the primary composite safety endpoint.

Time frame:
From Day 1 up to 6 months
Reported as:
Number · Participants
Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period
ParticipantsFSC DPIFP DPI
Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period265309
Statistical analysis
  • FSC DPI vs FP DPI · Hazard ratio (hr): 0.859 · 95% CI 0.729 to 1.012Estimated for Hazard ratio
SecondaryNumber of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period.

Number of participants experiencing asthma-related death over the 6-month study treatment period are presented.

Time frame:
From Day 1 up to 6 months
Reported as:
Number · Participants
Number of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period.
ParticipantsFSC DPIFP DPI
Number of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period.00
SecondaryNumber of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period

Intubation is defined as endotracheal intubation with ventilation (mechanical or by hand). The number of participants experiencing asthma-related endotracheal intubations over the 6-month study treatment period are presented.

Time frame:
From Day 1 up to 6 months
Reported as:
Number · Participants
Number of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period
ParticipantsFSC DPIFP DPI
Number of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period00
SecondaryNumber of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period

Hospitalization is defined as a \>=24-hour stay as an inpatient or in an observation ward. The number of participants experiencing asthma-related hospitalizations over the 6-month study treatment period are presented.

Time frame:
From Day 1 up to 6 months
Reported as:
Number · Participants
Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period
ParticipantsFSC DPIFP DPI
Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period2721
SecondaryNumber of Participants Withdrawn From Study Treatment Due to Asthma Exacerbation Over the 6-month Study Treatment Period

An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days (up to 10 days) or a single depot corticosteroid injection. Number of participants experiencing at least one exacerbation from mITT population were included for this endpoint. The number of participants withdrawn from study treatment due to asthma exacerbation over the 6-month study treatment period are presented.

Time frame:
From Day 1 up to 6 months
Reported as:
Number · Participants
Number of Participants Withdrawn From Study Treatment Due to Asthma Exacerbation Over the 6-month Study Treatment Period
ParticipantsFSC DPIFP DPI
Number of Participants Withdrawn From Study Treatment Due to Asthma Exacerbation Over the 6-month Study Treatment Period3335
SecondaryPercentage of Rescue-free Days Over the 6-month Study Treatment Period

Rescue-free days were days without use of rescue albuterol/salbutamol (other than pre-exercise treatment) over the 6-month study treatment period. The mean percentages of rescue-free days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.

Time frame:
From Day 1 up to 6 months
Reported as:
Mean · Percentage of rescue-free days
Percentage of Rescue-free Days Over the 6-month Study Treatment Period
Percentage of rescue-free daysFSC DPIFP DPI
Percentage of Rescue-free Days Over the 6-month Study Treatment Period83.0 ± 0.5081.9 ± 0.52
SecondaryPercentage of Asthma Control Days Over the 6-month Study Treatment Period

An asthma control day is one on which rescue albuterol/salbutamol use was recorded as 0, no night time awakenings were recorded, no asthma exacerbations were recorded, no work, school, or daycare days were missed by caregiver or participant due to asthma, coughing symptom score was \<=1 and wheezing symptom score was 0. The mean percentages of asthma control days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.

Time frame:
From Day 1 up to 6 months
Reported as:
Mean · Percentage of asthma control days
Percentage of Asthma Control Days Over the 6-month Study Treatment Period
Percentage of asthma control daysFSC DPIFP DPI
Percentage of Asthma Control Days Over the 6-month Study Treatment Period74.8 ± 0.5773.4 ± 0.58

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to 6 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FSC DPI—56/3,107 (1.8%)31/3,107 (1%)
FP DPI—54/3,101 (1.7%)39/3,101 (1.3%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventFSC DPIFP DPI
AsthmaRespiratory, thoracic and mediastinal disorders23/310713/3101
PneumoniaInfections and infestations11/31078/3101
BronchitisInfections and infestations3/31072/3101
Urinary tract infectionInfections and infestations1/31072/3101
GastroenteritisInfections and infestations0/31072/3101
TonsillitisInfections and infestations0/31072/3101
ConcussionInjury, poisoning and procedural complications1/31072/3101
Abdominal painGastrointestinal disorders0/31072/3101
AppendicitisInfections and infestations1/31071/3101
Lower respiratory tract infectionInfections and infestations1/31071/3101
Most frequent other events
Showing 10 of 31
Most frequent other events
EventFSC DPIFP DPI
AsthmaRespiratory, thoracic and mediastinal disorders15/310723/3101
CoughRespiratory, thoracic and mediastinal disorders2/31072/3101
HeadacheNervous system disorders2/31072/3101
Upper respiratory tract infectionInfections and infestations2/31070/3101
TremorNervous system disorders2/31070/3101
InsomniaPsychiatric disorders2/31070/3101
WheezingRespiratory, thoracic and mediastinal disorders1/31071/3101
DyspnoeaRespiratory, thoracic and mediastinal disorders0/31071/3101
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/31071/3101
Pharyngeal inflammationRespiratory, thoracic and mediastinal disorders0/31071/3101

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FSC DPIFP DPITotal
Mean7.6 ± 2.217.6 ± 2.207.6 ± 2.20
Sex: Female, Male
Sex: Female, Male(Participants)FSC DPIFP DPITotal
Female118712272414
Male192018743794
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FSC DPIFP DPITotal
African American / African Heritage5395111050
American Indian or Alaskan Native144118262
Asian - Central / South Asian Heritage303767
Asian - East Asian Heritage96112208
Japanese Heritage101
Asian - South East Asian Heritage122108230
Native Hawaiian or Other Pacific Islander516
White - Arabic / North African Heritage131528
White - White / Caucasian / European Heritage198520174002
Mixed Race167180347
Missing527
08

Study locations

532 sites
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Birmingham, Alabama 35233, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Montgomery, Alabama 36109, United States
  • GSK Investigational Site
    Scottsboro, Alabama 35768, United States
  • GSK Investigational Site
    Toney, Alabama 35773, United States
  • GSK Investigational Site
    Tuscaloosa, Alabama 35401, United States
  • GSK Investigational Site
    Dothan, Alaska 36305, United States
  • GSK Investigational Site
    Chandler, Arizona 85224, United States
  • GSK Investigational Site
    Phoenix, Arizona 85020, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85255, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85288, United States
  • GSK Investigational Site
    Tucson, Arizona 85724-5073, United States
  • GSK Investigational Site
    Tucson, Arizona 85741, United States
  • GSK Investigational Site
    Bentonville, Arkansas 72712, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72204, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72209, United States
  • GSK Investigational Site
    Alhambra, California 91801, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Canoga Park, California 91306, United States
  • GSK Investigational Site
    Dinuba, California 93618, United States
  • GSK Investigational Site
    Fresno, California 93703, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Gold River, California 95670, United States
  • GSK Investigational Site
    Granada Hills, California 91344, United States
  • GSK Investigational Site
    Harbor City, California 90710, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Huntington Park, California 90255, United States
  • GSK Investigational Site
    Long Beach, California 90807, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90057, United States
  • GSK Investigational Site
    Napa, California 94558, United States
  • GSK Investigational Site
    Newport Beach, California 92660, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Oakland, California 94609, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Palmdale, California 93551, United States
  • GSK Investigational Site
    Paramount, California 90723, United States
  • GSK Investigational Site
    Riverside, California 92501, United States
  • GSK Investigational Site
    Rolling Hills Est., California 920274, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    Roseville, California 95678, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    San Marino, California 91108, United States
  • GSK Investigational Site
    Santa Monica, California 90404, United States
  • GSK Investigational Site
    West Covina, California 91790, United States
  • GSK Investigational Site
    West Sacramento, California 95691, United States
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
  • GSK Investigational Site
    Centennial, Colorado 80112, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80920, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80922, United States
  • GSK Investigational Site
    Denver, Colorado 80206, United States
  • GSK Investigational Site
    Waterbury, Connecticut 06708, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Boynton Beach, Florida 33435, United States
  • GSK Investigational Site
    Cocoa, Florida 32927, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Destin, Florida 32541, United States
  • GSK Investigational Site
    Doral, Florida 33172, United States
  • GSK Investigational Site
    Gainesville, Florida 32605, United States
  • GSK Investigational Site
    Gainesville, Florida 32610, United States
  • GSK Investigational Site
    Hialeah, Florida 33012, United States
  • GSK Investigational Site
    Melbourne, Florida 32935, United States
  • GSK Investigational Site
    Miami Lakes, Florida 33016, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33135, United States
  • GSK Investigational Site
    Miami, Florida 33142, United States
  • GSK Investigational Site
    Miami, Florida 33144, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Miami, Florida 33175, United States
  • GSK Investigational Site
    Miami, Florida 33176, United States
  • GSK Investigational Site
    Miami, Florida 33184, United States
  • GSK Investigational Site
    Naples, Florida 34102, United States
  • GSK Investigational Site
    New Port Richey, Florida 34652, United States
  • GSK Investigational Site
    Ocala, Florida 34471, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Orlando, Florida 32811, United States
  • GSK Investigational Site
    Orlando, Florida 32822, United States
  • GSK Investigational Site
    Pace, Florida 32571, United States
  • GSK Investigational Site
    Pensacola, Florida 32503, United States
  • GSK Investigational Site
    Pensacola, Florida 32514, United States
  • GSK Investigational Site
    Ponte Vedra Beach, Florida 32081, United States
  • GSK Investigational Site
    Saint Cloud, Florida 34769, United States
  • GSK Investigational Site
    Saint Petersburg, Florida 33701, United States
  • GSK Investigational Site
    Saint Petersburg, Florida 33710, United States
  • GSK Investigational Site
    Tampa, Florida 33606, United States
  • GSK Investigational Site
    Tampa, Florida 33613, United States
  • GSK Investigational Site
    Wellington, Florida 33414, United States
  • GSK Investigational Site
    Augusta, Georgia 30909, United States
  • GSK Investigational Site
    Calhoun, Georgia 30701, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Gainesville, Georgia 30501, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30045, United States
  • GSK Investigational Site
    Lilburn, Georgia 30047, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States

Showing the first 100 of 532 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lee LA, Pedersen S, Pascoe SJ, Szefler SJ, Lenney W. No dose effect observed with chronic fluticasone propionate on growth velocity in children. Pediatr Allergy Immunol. 2021 Feb;32(2):377-381. doi: 10.1111/pai.13378. Epub 2020 Oct 26. No abstract available. PubMed 32966707 ↗
  • Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ; VESTRI Investigators. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. N Engl J Med. 2016 Sep 1;375(9):840-9. doi: 10.1056/NEJMoa1606356. PubMed 27579634 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2011
First posted
Oct 31, 2011
Start
Nov 17, 2011
Primary completionActual
Nov 1, 2015
CompletionActual
Nov 3, 2015
Results first posted
Oct 5, 2016
Last update
Aug 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01462344
Lead sponsor
GlaxoSmithKline
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 31, 2011
Start date
Nov 17, 2011
Primary completion
Nov 1, 2015
Completion
Nov 3, 2015
Results posted
Oct 5, 2016
Last update
Aug 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion